基于连接体的虚拟查发现了一种新的CFTR连接体,它可以改善错误折叠的ABC载体的缺陷细胞表面表达
Shogo Taniguchi1, Francois Berenger2, Yukako Doi1
1Department of Biomedical Sciences, School of Biological and Environmental Sciences, Kwansei Gakuin University, Nishinomiya, Japan.
Frontiers in pharmacology
|April 26, 2024
概括
一种新的化合物FR3通过稳定其结构来增强囊性纤维化跨膜导电性调节器 (CFTR) 蛋白的功能. FR3为囊性纤维化 (CF) 和其他ABC载体疾病提供了一种新的治疗方法.
科学领域:
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
- 遗传疾病 遗传疾病
背景情况:
- 囊性纤维化 (CF) 是一种由囊性纤维化跨膜导电性调节器 (CFTR) 基因突变引起的单遗传性疾病.
- 最常见的CFTR突变,ΔF508,导致蛋白质错折,内质网膜 (ER) 保留和过早降解,阻止其在顶端等离子体膜 (PM) 的功能.
- 目前的CFTR调节器,如Trikafta (TEZ/ELX/IVA),可以改善ΔF508-CFTR功能,但不能完全解决蛋白质稳定问题.
研究的目的:
- 确定具有独特作用机制的新型CFTR调节剂,以改善ΔF508-CFTR功能表达.
- 研究一种新发现的化合物FR3的治疗潜力,用于CF和其他与ABC输送器功能障碍相关的疾病.
主要方法:
- 基于现有的CFTR调节器结构对大约430万种化合物的虚拟选.
- 评估FR3对ΔF508-CFTR在气道上皮质细胞系中的功能表达和稳定性的影响.
- 评估FR3对成熟的ΔF508-CFTR降解的影响及其对错误折叠的ABCB1突变物的影响.
主要成果:
- 鉴定FR3,一种具有独特作用机制的新型CFTR配体.
- 通过稳定核酸结合域1 (NBD1) 的作用,FR3增强了峰PM的ΔF508-CFTR功能表达.
- FR3 抵消成熟的 ΔF508-CFTR 的降解,并纠正错误折叠的 ABCB1 突变体中的 PM 表达缺陷.
结论:
- 通过解决 ΔF508-CFTR 稳定性,FR3 是一种有前途的治疗性化合物,用于囊性纤维化.
- FR3的独特机制为治疗CF和其他由ABC输送器错误折叠引起的疾病提供了潜力.
- 对FR3的进一步研究可能会导致改善一系列遗传疾病的治疗方法.
更多相关视频
07:04Forskolin-induced Swelling in Intestinal Organoids: An In Vitro Assay for Assessing Drug Response in Cystic Fibrosis Patients
Published on: February 11, 2017
19.2K
04:15Author Spotlight: Development of a Method for Identifying Small Molecular Antagonists of β2 Integrin Activation
Published on: February 2, 2024
1.8K
相关概念视频
ABC Transporters: Exporter
5.7K
ATP-binding cassette or ABC transporter is the largest superfamily of integral membrane proteins. The transporters have transmembrane-binding domains (TMDs) and nucleotide-binding domains (NBDs). The TMDs are specific to their substrates, whereas the NBDs are similar to engines that complete ATP hydrolysis to complete the substrate transport. They can be full transporters consisting of two TMDs and NBDs, half transporters with one TMD and NBD, while some encoded with a single TMD or NBD are...
5.7K
Pharmacogenomics: Identification of New Drug Targets
129
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
129
